Mk-7262

Phase 2

Merck & Co.

Mk-7262 is one of 2 therapeutic programs targeting Lipoprotein(a). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lipoprotein(a)Recruiting

Lipoprotein(a)Phase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Lipoprotein(a)

#DrugCompanyPhaseTrials

Enlicitide

Merck & Co.

Phase 2

1 2

Mk-7262

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Study completion

NCT07619443

Q4 2027

Phase 2Recruiting

Lipoprotein(a)

NCT07614984

Clinical

Trials by Indication[1]

Lipoprotein(a)1 trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07614984·750 enrolled

Unspecified1 trial

A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07619443·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mk-7262. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mk-7262. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Merck & Co.

Mk-7262

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Lipoprotein(a)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News